Drugs / GCB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06772402 | Jan 2025 → Dec 2026 expected | spinal muscular atrophy, type II | Genecombio Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06772402 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “self-complementary AAV9 carrying a full length human SMN transgenetic product” NCT06772402 ↗ |
| Route | Intrathecal | “single intrathecal injection” NCT06772402 ↗ |